Up-front blinatumomab improves MRD clearance and outcome in adult Ph- B-lineage ALL: The GIMEMA LAL2317 phase 2 study
Last Updated: Thursday, March 27, 2025
The GIMEMA LAL2317 protocol investigated a chemotherapy-blinatumomab combination for adult Ph- B-ALL. This approach significantly improved the MRD negativity rate to 93% after blinatumomab treatment. The estimated 3-year survival rate for blinatumomab-treated patients was 82%. Blinatumomab toxicity was manageable. The study suggests blinatumomab should be considered a standard component for adult Ph- B-ALL.
Advertisement
News & Literature Highlights